bought a ton in the six dollar range held it much longer than I'd hoped for,...buyout completed, although I'd hoped for a better price.
Key Details of the AVDL Buyout:
- Total Value: ~$2.37 Billion (up to $22.50 per share).
- Cash Component: $21.00 per share upfront.
- Contingent Value Right (CVR): Up to $1.50 per share based on the final FDA approval of Lumryz for adult idiopathic hypersomnia by December 2028.
- Closing Date: Expected in Q1 2026.
Boom
